Ultragenyx, GeneTx Provide Preliminary Update On Phase 1/2 Clinical Study Of GTX-102 In Canada And UK Patients With Angelman Syndrome
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, today announced that the first four
Ultragenyx, GeneTx Report Will Participate In FAST Global Summit, Gala Dec. 4
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), companies partnered in the development of GTX-102, today announced multiple presentations at the 2021 FAST Global Summit & Gala,
Ultragenyx Pharmaceutical Q3 EPS $(1.08) Beats $(1.41) Estimate, Sales $81.65M Beat $81.55M Estimate
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.41) by 23.4 percent. This is a 4.42 percent increase over losses of $(1.13) per
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
GeneTx And Ultragenyx Announce First Patient Dosed In Canada In Phase 1/2 Clinical Trial Of GTX-102 In Patients With Angelman Syndrome
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), companies partnered in the development of GTX-102, an investigational treatment for Angelman syndrome, today announced that the first patient
Mereo BioPharma And Ultragenyx Present Data From Phase 2b ASTEROID Study Of UX143 (setrusumab) In Osteogenesis Imperfecta (OI) At American Society For Bone And Mineral Research (ASBMR) 2021 Annual Meeting
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, and Mereo BioPharma Group plc
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Over the past 3 months, 4 analysts have published their opinion on Ultragenyx Pharmaceutical (NASDAQ:RARE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.